While no published pre-clinical information is available, the orally active, potent and selective CBP/p300 bromodomain inhibitor FT-7051 has entered a multi-center, phase I, open-label clinical trial in patients with metastatic castration-resistant prostate cancer (ClinicalTrials.gov Identifier NCT04575766) 111. Here, CREBBP is linked to prostate carcinoma.